Zura Bio (ZURA) Net Income towards Common Stockholders (2022 - 2026)

Zura Bio's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$24.2 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 38.88% year-over-year to -$24.2 million in Q1 2026; TTM through Mar 2026 was -$106.1 million, a 70.91% decrease from a year earlier, with the FY2025 full-year figure at -$99.4 million, down 118.91% from the prior year.
• Net Income towards Common Stockholders rose to -$24.2 million in Q1 2026 per ZURA's latest filing, from -$45.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$730000.0 in Q1 2024 and bottomed at -$45.9 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$12.7 million (2024), against an average of -$15.9 million.
• Across the five-year window, Net Income towards Common Stockholders sank 4754.05% in 2023 and jumped 92.55% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$22.5 million in 2022, then jumped by 72.15% to -$6.3 million in 2023, then tumbled by 44.12% to -$9.0 million in 2024, then plunged by 407.08% to -$45.9 million in 2025, then soared by 47.2% to -$24.2 million in 2026.
• Per Business Quant, the three latest ZURA Net Income towards Common Stockholders figures stand at -$24.2 million (Q1 2026), -$45.9 million (Q4 2025), and -$20.0 million (Q3 2025).